BNP/CALL/ASTRAZENECA/11000/0.1/20.12.24 Stock

DE000PC3BU25

Real-time Boerse Frankfurt Warrants 04:20:45 2024-06-10 am EDT
2.48 ^EUR	+0.81%

Current month	+16.04%
1 month	+17.70%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/11000/0.1/20.12.24

Latest news about ASTRAZENECA PLC

JPMorgan cuts Aviva but lifts M&G	04:12am	AN
Investors remain cautious as political instability takes over Europe	04:04am
AstraZeneca: priority review in the USA for Tagrisso	04:02am	CF
Astra's Tagrisso gets US priority review for lung cancer	03:32am	AN

More news

Quotes 5-day view

Date	Price	Change
24-06-10	2.48	+0.81%
24-06-07	2.46	0.00%
24-06-06	2.46	0.00%
24-06-05	2.46	+5.58%
24-06-04	2.33	+2.19%

Real-time Boerse Frankfurt Warrants

Last update June 10, 2024 at 04:20 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC3BU2
ISIN	DE000PC3BU25
Date issued	2024-01-16
Strike	11,000 p
Maturity	2024-12-20 (194 Days)
Parity	10 : 1
Emission price	1.12 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.48 €
Lowest since issue	0.43 €
Spread	0.02 €
Spread %	0.80%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company